Phase 1 N=78 Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers
Safety and Tolerability of EGT0001474 in Healthy Volunteers
Primary: Cmax — 12.7; 28; 90.7; 194 ng/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=60 Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169
Healthy Subjects
Primary: Number of Adverse Events — 9; 4; 5; 2 AEs
Phase 1 N=24 Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes
Diabetes Mellitus Type 2
Primary: Safety and Tolerability of EGT0001474 — 5; 0; 9; 3 Events
Phase 1 N=280 Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 88; 27 Participants
Phase 1 N=32 A Study of RGLS8429 in Healthy Volunteers
Healthy Volunteers
Primary: Incidence of Adverse Events (AEs) — 0; 0; 0; 0 participants
Phase 1 N=9 Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
Healthy
Primary: Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) Post-Baseline — 0; 0; 0; 0 participants
Phase 1 N=47 Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants
Dose Finding Study
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event — 0; 16.7; 0; 16.7 percentage of participants
Phase 1 N=120 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 1 Single-rising Dose (SRD) — 11.1; 0; 0; 16.7 percentage of…
Phase 1 N=66 Phase 1 Study for IPG11406 in Health Volunteer
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
Phase 1 N=70 Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Male Volunteers
Healthy
Primary: Number (%) of Subjects With Drug Related Adverse Events — 0.0; 33.3; 16.7; 0.0 Percentage of Participants
Phase 1 N=51 A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects
Healthy Volunteers
Primary: Maximal Plasma Concentration (Cmax) of AGN-223575 — 0.186; 0.128; 0.114; NA Nanograms/Milliliters (ng/mL)
Phase 1 N=76 Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants
Healthy Volunteers
Primary: Adverse Events — 0; 2; 3; 3 Participants
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=48 Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants
Dose Finding Study
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 16.7; 0; 50.0; 0 percentage of participants
Phase 2 N=149 Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2
Primary: Changes in Fasting Plasma Glucose (FPG) From Baseline at Week 4 for Segment 2 of the Study — -12.595; -29.518; -30.429; -32.586 mg/dL — p=0.0989
Phase 1 N=72 Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants
Phase 1 N=32 Safety, Tolerability and Pharmacokinetics of Etelcalcetide in Healthy Male Volunteers
Hyperparathyroidism, Secondary
Primary: Number of Participants With Adverse Events — 2; 0; 1; 2 participants
Phase 1 N=97 Safety, Tolerability and Pharmacokinetics of AM1476 in Healthy Subjects
Safety · Tolerability
Primary: Number of Participants With Treatment-Emergent Adverse Events — 3; 0; 0; 4 Participants
Phase 1 N=41 Trial to Investigate GZ21T in Healthy Volunteers
Actinic Keratosis
Primary: AE — 3; 0; 2; 3 participants
Phase 1 N=40 Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants
Healthy Volunteers
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event — 50.0; 50.0; 33.3; 66.7 percentage of participants
Phase 1 N=70 Safety, Tolerability and PK of Repeat Administration of Intravenous ETI-204 in Adult Volunteers
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 30; 31 Participants
Phase 1 N=6 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
Healthy
Primary: Number of Treatment Related Adverse Events — 3; 4; 0; 3 Number of events
Phase 1 N=48 Cardiac Safety Evaluation of P03277
Healthy Volunteers
Primary: Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF) — 0.97; 5.05; 0.24; -0.11 milliseconds
Phase 1 N=41 Safety and Tolerability Study of N6022 in Healthy Subjects
Healthy
Primary: Safety and Tolerability of a Single Ascending Doses of Intravenous N6022 in Healthy Volunteers — 1; 4; 1; 0 Adverse Events
Phase 1 N=97 Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers
Healthy
Primary: Number (%) of Subjects With Drug-related Adverse Events — 28.0; 51.9; 33.3; 92.6 Percentage of participants
Phase 1 N=72 Single-Dose Phase 1 Study of TAK-792
Healthy Male Adults Participants
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 16.7; 16.7; 0.0; 33.3 percentage of participants
Phase 1 N=83 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses
Healthy
Primary: Number of Young and Elderly Subjects With On-treatment Adverse Events by Treatment Group — 6; 3; 5; 6 Participants
Phase 1 N=48 Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 33.3; 33.3; 22.2; 88.9 percentage of participants
Phase 1 N=62 Safety Tolerability and Pharmacokinetic of BI 411034
Healthy
Primary: Number of Participants With Drug Related AEs — 1; 0; 0; 1 participants
Phase 1 N=87 A Study in Healthy Men and Women to Test How Well Different Doses of BI 1323495 Are Tolerated
Healthy
Primary: Percentage of Participants With Treatment-emergent Drug-related Adverse Events (AEs) — 4.5; 0; 22.2; 0 percentage of participants